News

As part of the project, the company considers expanding clean room molding and assembly capacity in addition to launching art logistics system designed to control the flow of

The application was supported by data from Phase III study of trametinib monotherapy compared to dacarbazine monotherapy conducted in metastatic melanoma patients with BRAF V600 mutation. Data from

The 16,000ft² facility is the fourth center of excellence of Ansell while the other three include Malaysia, Mexico and North America-based centers. Ansell managing director and CEO Magnus

Apogenix also announced the commencement of Apocept Phase I trial in MDS patients in Germany. Endpoints of the open-label study include efficacy (improvement of erythropoiesis), safety, and tolerability

Combining the needs of multiple commercial teams, Veeva’s CRM solution improves user adoption and sales effectiveness, while reduces cost and complexity. iRep, a transformative sales effectiveness tool, combines

Under the agreement, DNA Link gained licensing rights to leverage Affymetrix’ microarray technology and the KFDA-cleared GeneChip System 3000Dx v.2 to develop and commercialize a forensic test AccuIDChip,

As part of the analysis, performed at more than 80 US locations, patients were given the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) and evaluated

Warner expects to commercially launch Delzicol in March 2013. Delzicol delayed-release capsules are indicated to treat patients with mild to moderate active ulcerative colitis and to maintain remission

Skyepharma received the notice of allowance for US patent application 13/428,548 entitled ‘Delayed Release Tablet with Defined Core Geometry’. The US patent planned to issue will expire in